<DOC>
	<DOCNO>NCT01464021</DOCNO>
	<brief_summary>A post-marketing uncontrolled observational study explore describe effectiveness adalimumab , prescribe accord local product label , patient moderately severely active rheumatoid arthritis ( RA ) China .</brief_summary>
	<brief_title>A Post-Marketing Observational Study Evaluate Effectiveness Adalimumab Patients With Moderately Severely Active Rheumatoid Arthritis China</brief_title>
	<detailed_description>This post-marketing , multi-center , uncontrolled observational study conduct open-label , non-interventional setting , RA patient use commercially available adalimumab administer subcutaneously ( SC ) . Adalimumab effectiveness assess base data clinic visit begin Baseline continue per standard care RA . The primary objective evaluate effectiveness adalimumab improve patient ' disease activity measure Disease Activity Score ( DAS28 ) Week 12 . The maximum observation period patient approximately 52 week , long patient continue receive adalimumab injection . The study terminate due low enrollment .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Male female patient great equal 18 year age diagnosis RA ( Rheumatoid Arthritis ) history chronic arthritis age 16 . 2 . Patient meet requirement treatment adalimumab per local product label . 3 . Patient na√Øve adalimumab , use immunomodulatory biologic* DMARD ( Disease Modifying Antirheumatic Drugs ) past 8 week Baseline visit ( *rituximab may use past 104 week Baseline visit ) . 4 . Patient must able willing provide write authorization ( informed consent applicable ) disclose use personal health information comply requirement study protocol well agree data collect Abbott . 1 . Patient currently treat treated investigational drug chemical biologic nature within minimum 30 day five half life ( whichever longer ) drug prior Baseline visit . 2 . Prior clinically active TB ( tuberculosis ) : patient prior clinically active TB , documentation full course appropriate antiTB therapy complete ongoing full course appropriate antiTB therapy start initiation adalimumab accordance local product label ; otherwise , patient eligible participate study . 3 . Patient intend take less 6 consecutive ( every week ) injection adalimumab . 4 . Patients enrol treated adalimumab accordance local product label Investigator determine enrol base his/her clinical judgment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Study</keyword>
	<keyword>prospective</keyword>
	<keyword>Rheumatoid</keyword>
	<keyword>Observational study</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Adalimumab</keyword>
</DOC>